Since genomic alterations change as a cancer evolves, how do we employ whole exome genomic profiling as part of a longitudinal patient management strategy? (Korean)

Since genomic alterations change as a cancer evolves, how do we employ whole exome genomic profiling as part of a longitudinal patient management strategy? (Korean)

Since genomic alterations change as a cancer evolves, how do we employ whole exome genomic profiling as part of a longitudinal patient management strategy?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Professor Byoung Chul Cho, MD, PhD

Professor Byoung Chul Cho, MD, PhD

Yonsei Cancer Center Yonsei University College of Medicine J JE-UK Laboratory of Molecular Cancer Therapeutics Seoul, Korea